Share Price and Basic Stock Data
Last Updated: December 3, 2025, 8:37 pm
| PEG Ratio | -37.63 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Arvee Laboratories (India) Ltd operates within the specialty chemicals sector, focusing on niche chemical products. As of the latest reporting period, the company recorded sales of ₹38.49 Cr for the fiscal year ending March 2025, a decline from ₹61.35 Cr in March 2023. This drop reflects a challenging market environment, compounded by a quarterly sales slump to ₹6.14 Cr in March 2024, followed by a slight recovery to ₹7.48 Cr by June 2025. The company’s sales trajectory has been volatile, with a peak of ₹22.74 Cr in September 2022, indicating fluctuations in demand for its products. Over the same period, the operating profit margin (OPM) averaged around 9.38%, showcasing a need for strategic pricing and cost management to enhance profitability. The company’s performance is further illustrated by its trailing twelve months (TTM) sales of ₹35.37 Cr, indicating a downward trend compared to earlier years. This pattern raises concerns about sustaining revenue growth, especially considering the competitive landscape and operational challenges faced by the specialty chemicals segment.
Profitability and Efficiency Metrics
Arvee Laboratories reported a net profit of ₹2.15 Cr for the fiscal year ending March 2025, a recovery from ₹1.05 Cr in March 2024 but down from ₹4.12 Cr in March 2023. The company’s profit margins have been under pressure, with the net profit margin standing at 5.57% for the latest fiscal year, compared to 6.71% in the previous year. The operating profit margin (OPM) has also shown a declining trend, recording 9.38% in March 2025 against 11.88% in March 2023. Efficiency metrics are mixed, with the Interest Coverage Ratio (ICR) reported at a robust 17.19x, indicating strong ability to meet interest obligations. However, the Cash Conversion Cycle (CCC) increased to 102.25 days in March 2025, reflecting potential inefficiencies in managing working capital. Such a high CCC may hinder liquidity and operational flexibility, emphasizing the need for improved inventory and receivables management to enhance operational efficiency.
Balance Sheet Strength and Financial Ratios
The balance sheet of Arvee Laboratories reflects a conservative financial structure, with total borrowings recorded at ₹1.03 Cr as of March 2025, against total equity of ₹20.42 Cr in reserves, resulting in a Debt-to-Equity ratio of 0.03. This low leverage ratio suggests a low-risk profile, positioning the company well for financial stability. The company’s current ratio stood at 5.14x, indicating strong short-term liquidity and ability to meet current liabilities. However, the Price-to-Book Value (P/BV) ratio of 5.01x is relatively high compared to typical sector norms, suggesting that the market may be pricing in future growth potential despite current profitability challenges. Furthermore, the Return on Capital Employed (ROCE) is reported at 10.00%, reflecting decent capital efficiency, although it has declined from previous levels. Overall, while the company maintains a strong balance sheet, its profitability metrics indicate pressures that could affect long-term sustainability.
Shareholding Pattern and Investor Confidence
As of March 2025, the shareholding structure of Arvee Laboratories consists of 73.50% held by promoters, indicating a strong controlling interest that may align with long-term strategic goals. The remaining 26.50% is held by the public, with the number of shareholders increasing to 1,505, reflecting growing interest from retail investors. This stable promoter holding can instill confidence among investors regarding the company’s governance and operational direction. However, the absence of Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) suggests limited institutional interest, which could impact stock liquidity. Despite this, the consistent promoter stake could be viewed positively, as it may indicate commitment to the company’s growth. The lack of dividends over the years further underscores a focus on reinvestment rather than immediate shareholder returns, which could resonate well with growth-focused investors but may deter those seeking income.
Outlook, Risks, and Final Insight
Looking ahead, Arvee Laboratories faces both opportunities and risks. On the positive side, the company’s strong liquidity position, as indicated by a current ratio of 5.14x, allows for potential investments in growth initiatives. However, the declining sales and profitability metrics raise concerns about the sustainability of its business model in a competitive specialty chemicals market. Risks include high operational costs reflected in the fluctuating operating profit margins and challenges in managing the cash conversion cycle. Additionally, the absence of institutional backing may limit the stock’s growth potential. In the event of a market recovery and improved operational efficiencies, the company could regain profitability and enhance shareholder value. Conversely, continued revenue decline may necessitate strategic pivots or cost-cutting measures to maintain financial health. The path forward will require careful navigation of these dynamics to ensure long-term viability and growth.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Arvee Laboratories (India) Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| HP Adhesives Ltd | 400 Cr. | 43.5 | 86.7/42.2 | 24.9 | 20.5 | 0.92 % | 13.6 % | 9.82 % | 2.00 |
| Haryana Leather Chemicals Ltd | 33.3 Cr. | 67.8 | 103/56.0 | 15.9 | 89.6 | 1.47 % | 8.02 % | 5.45 % | 10.0 |
| Hardcastle & Waud Mfg Co Ltd | 45.7 Cr. | 672 | 988/600 | 21.0 | 697 | 0.00 % | 6.31 % | 2.91 % | 10.0 |
| Grauer & Weil (India) Ltd | 3,397 Cr. | 74.9 | 111/74.5 | 22.5 | 22.0 | 0.67 % | 23.3 % | 17.6 % | 1.00 |
| DMCC Speciality Chemicals Ltd | 680 Cr. | 273 | 453/241 | 24.4 | 93.8 | 0.92 % | 14.1 % | 9.97 % | 10.0 |
| Industry Average | 12,715.00 Cr | 715.03 | 62.40 | 183.02 | 0.43% | 12.99% | 25.41% | 6.41 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 18.18 | 22.74 | 16.25 | 12.56 | 7.60 | 8.91 | 7.70 | 6.14 | 10.60 | 12.53 | 8.91 | 6.45 | 7.48 |
| Expenses | 15.92 | 19.48 | 14.51 | 11.40 | 6.62 | 8.22 | 7.17 | 5.35 | 9.06 | 11.03 | 8.57 | 6.23 | 7.14 |
| Operating Profit | 2.26 | 3.26 | 1.74 | 1.16 | 0.98 | 0.69 | 0.53 | 0.79 | 1.54 | 1.50 | 0.34 | 0.22 | 0.34 |
| OPM % | 12.43% | 14.34% | 10.71% | 9.24% | 12.89% | 7.74% | 6.88% | 12.87% | 14.53% | 11.97% | 3.82% | 3.41% | 4.55% |
| Other Income | 0.02 | 0.06 | 0.07 | 0.06 | 0.09 | 0.09 | 0.19 | 0.21 | 0.11 | 0.16 | 0.19 | 0.21 | 0.17 |
| Interest | 0.11 | 0.11 | 0.09 | 0.07 | 0.07 | 0.08 | 0.05 | 0.05 | 0.08 | 0.05 | 0.05 | 0.07 | 0.04 |
| Depreciation | 0.64 | 0.48 | 0.49 | 0.48 | 0.35 | 0.42 | 0.35 | 0.37 | 0.31 | 0.30 | 0.28 | 0.27 | 0.29 |
| Profit before tax | 1.53 | 2.73 | 1.23 | 0.67 | 0.65 | 0.28 | 0.32 | 0.58 | 1.26 | 1.31 | 0.20 | 0.09 | 0.18 |
| Tax % | 24.84% | 25.27% | 25.20% | 100.00% | 24.62% | 25.00% | 25.00% | 81.03% | 25.40% | 25.19% | 25.00% | 22.22% | 5.56% |
| Net Profit | 1.14 | 2.05 | 0.92 | 0.01 | 0.49 | 0.21 | 0.24 | 0.12 | 0.94 | 0.98 | 0.15 | 0.07 | 0.17 |
| EPS in Rs | 1.03 | 1.86 | 0.83 | 0.01 | 0.44 | 0.19 | 0.22 | 0.11 | 0.85 | 0.89 | 0.14 | 0.06 | 0.15 |
Last Updated: August 20, 2025, 1:35 pm
Below is a detailed analysis of the quarterly data for Arvee Laboratories (India) Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 7.48 Cr.. The value appears strong and on an upward trend. It has increased from 6.45 Cr. (Mar 2025) to 7.48 Cr., marking an increase of 1.03 Cr..
- For Expenses, as of Jun 2025, the value is 7.14 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6.23 Cr. (Mar 2025) to 7.14 Cr., marking an increase of 0.91 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.34 Cr.. The value appears strong and on an upward trend. It has increased from 0.22 Cr. (Mar 2025) to 0.34 Cr., marking an increase of 0.12 Cr..
- For OPM %, as of Jun 2025, the value is 4.55%. The value appears strong and on an upward trend. It has increased from 3.41% (Mar 2025) to 4.55%, marking an increase of 1.14%.
- For Other Income, as of Jun 2025, the value is 0.17 Cr.. The value appears to be declining and may need further review. It has decreased from 0.21 Cr. (Mar 2025) to 0.17 Cr., marking a decrease of 0.04 Cr..
- For Interest, as of Jun 2025, the value is 0.04 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.07 Cr. (Mar 2025) to 0.04 Cr., marking a decrease of 0.03 Cr..
- For Depreciation, as of Jun 2025, the value is 0.29 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.27 Cr. (Mar 2025) to 0.29 Cr., marking an increase of 0.02 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.18 Cr.. The value appears strong and on an upward trend. It has increased from 0.09 Cr. (Mar 2025) to 0.18 Cr., marking an increase of 0.09 Cr..
- For Tax %, as of Jun 2025, the value is 5.56%. The value appears to be improving (decreasing) as expected. It has decreased from 22.22% (Mar 2025) to 5.56%, marking a decrease of 16.66%.
- For Net Profit, as of Jun 2025, the value is 0.17 Cr.. The value appears strong and on an upward trend. It has increased from 0.07 Cr. (Mar 2025) to 0.17 Cr., marking an increase of 0.10 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.15. The value appears strong and on an upward trend. It has increased from 0.06 (Mar 2025) to 0.15, marking an increase of 0.09.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 22, 2025, 5:24 pm
| Metric | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 26.82 | 34.44 | 47.78 | 54.90 | 45.42 | 47.38 | 40.33 | 61.35 | 30.35 | 38.49 | 35.37 |
| Expenses | 21.83 | 28.54 | 40.61 | 48.73 | 39.40 | 41.31 | 34.65 | 54.06 | 27.41 | 34.88 | 32.97 |
| Operating Profit | 4.99 | 5.90 | 7.17 | 6.17 | 6.02 | 6.07 | 5.68 | 7.29 | 2.94 | 3.61 | 2.40 |
| OPM % | 18.61% | 17.13% | 15.01% | 11.24% | 13.25% | 12.81% | 14.08% | 11.88% | 9.69% | 9.38% | 6.79% |
| Other Income | 0.10 | 0.51 | 0.23 | 0.35 | 0.35 | 0.56 | 0.46 | 1.35 | 0.64 | 0.66 | 0.73 |
| Interest | 3.07 | 3.48 | 3.33 | 1.63 | 0.99 | 0.58 | 0.37 | 0.39 | 0.25 | 0.25 | 0.21 |
| Depreciation | 1.49 | 2.07 | 2.15 | 2.35 | 2.29 | 2.41 | 2.32 | 2.08 | 1.50 | 1.15 | 1.14 |
| Profit before tax | 0.53 | 0.86 | 1.92 | 2.54 | 3.09 | 3.64 | 3.45 | 6.17 | 1.83 | 2.87 | 1.78 |
| Tax % | 66.04% | -81.40% | 43.23% | 11.02% | 25.89% | 26.37% | 25.51% | 33.23% | 42.62% | 25.09% | |
| Net Profit | 0.19 | 1.55 | 1.09 | 2.26 | 2.30 | 2.68 | 2.57 | 4.12 | 1.05 | 2.15 | 1.37 |
| EPS in Rs | 0.23 | 1.91 | 0.99 | 2.05 | 2.09 | 2.43 | 2.33 | 3.74 | 0.95 | 1.95 | 1.24 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 715.79% | -29.68% | 107.34% | 1.77% | 16.52% | -4.10% | 60.31% | -74.51% | 104.76% |
| Change in YoY Net Profit Growth (%) | 0.00% | -745.47% | 137.02% | -105.57% | 14.75% | -20.63% | 64.42% | -134.83% | 179.28% |
Arvee Laboratories (India) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -3% |
| 3 Years: | -2% |
| TTM: | 6% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 0% |
| 3 Years: | -5% |
| TTM: | -9% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 35% |
| 3 Years: | 22% |
| 1 Year: | -12% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 10% |
| 3 Years: | 9% |
| Last Year: | 7% |
Last Updated: September 4, 2025, 11:40 pm
Balance Sheet
Last Updated: December 4, 2025, 12:58 am
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.05 | 4.05 | 5.51 | 5.51 | 5.51 | 11.02 | 11.02 | 11.02 | 11.02 | 11.02 | 11.02 |
| Reserves | -1.41 | 0.15 | 8.69 | 10.95 | 13.25 | 10.42 | 12.92 | 17.04 | 18.09 | 20.24 | 20.42 |
| Borrowings | 25.32 | 24.99 | 16.15 | 12.87 | 3.87 | 8.88 | 3.13 | 1.00 | 1.00 | 1.03 | 1.03 |
| Other Liabilities | 7.25 | 6.49 | 13.77 | 7.81 | 11.00 | 10.73 | 11.61 | 9.63 | 8.08 | 5.87 | 8.11 |
| Total Liabilities | 35.21 | 35.68 | 44.12 | 37.14 | 33.63 | 41.05 | 38.68 | 38.69 | 38.19 | 38.16 | 40.58 |
| Fixed Assets | 13.15 | 16.88 | 14.88 | 12.65 | 13.18 | 13.81 | 13.84 | 12.68 | 12.67 | 15.27 | 15.25 |
| CWIP | 4.30 | -0.00 | 1.18 | 2.32 | 1.78 | 0.97 | 0.98 | 1.53 | 2.62 | 0.73 | 0.81 |
| Investments | -0.00 | -0.00 | -0.00 | 1.95 | 3.09 | 2.03 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Other Assets | 17.76 | 18.80 | 28.06 | 20.22 | 15.58 | 24.24 | 23.86 | 24.48 | 22.90 | 22.16 | 24.52 |
| Total Assets | 35.21 | 35.68 | 44.12 | 37.14 | 33.63 | 41.05 | 38.68 | 38.69 | 38.19 | 38.16 | 40.58 |
Below is a detailed analysis of the balance sheet data for Arvee Laboratories (India) Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 11.02 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 11.02 Cr..
- For Reserves, as of Sep 2025, the value is 20.42 Cr.. The value appears strong and on an upward trend. It has increased from 20.24 Cr. (Mar 2025) to 20.42 Cr., marking an increase of 0.18 Cr..
- For Borrowings, as of Sep 2025, the value is 1.03 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 1.03 Cr..
- For Other Liabilities, as of Sep 2025, the value is 8.11 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.87 Cr. (Mar 2025) to 8.11 Cr., marking an increase of 2.24 Cr..
- For Total Liabilities, as of Sep 2025, the value is 40.58 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 38.16 Cr. (Mar 2025) to 40.58 Cr., marking an increase of 2.42 Cr..
- For Fixed Assets, as of Sep 2025, the value is 15.25 Cr.. The value appears to be declining and may need further review. It has decreased from 15.27 Cr. (Mar 2025) to 15.25 Cr., marking a decrease of 0.02 Cr..
- For CWIP, as of Sep 2025, the value is 0.81 Cr.. The value appears strong and on an upward trend. It has increased from 0.73 Cr. (Mar 2025) to 0.81 Cr., marking an increase of 0.08 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 24.52 Cr.. The value appears strong and on an upward trend. It has increased from 22.16 Cr. (Mar 2025) to 24.52 Cr., marking an increase of 2.36 Cr..
- For Total Assets, as of Sep 2025, the value is 40.58 Cr.. The value appears strong and on an upward trend. It has increased from 38.16 Cr. (Mar 2025) to 40.58 Cr., marking an increase of 2.42 Cr..
Notably, the Reserves (20.42 Cr.) exceed the Borrowings (1.03 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -20.33 | -19.09 | -8.98 | -6.70 | 2.15 | -2.81 | 2.55 | 6.29 | 1.94 | 2.58 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 82.61 | 87.12 | 118.25 | 52.66 | 52.40 | 60.70 | 109.78 | 72.94 | 73.48 | 79.66 |
| Inventory Days | 155.08 | 104.53 | 99.61 | 42.90 | 80.96 | 91.96 | 93.24 | 42.29 | 159.02 | 80.31 |
| Days Payable | 130.73 | 98.14 | 150.03 | 55.84 | 125.63 | 118.08 | 160.12 | 73.30 | 164.49 | 57.72 |
| Cash Conversion Cycle | 106.96 | 93.50 | 67.84 | 39.72 | 7.72 | 34.59 | 42.90 | 41.94 | 68.01 | 102.25 |
| Working Capital Days | 30.08 | 30.84 | 30.79 | -6.52 | 10.29 | -10.63 | 49.96 | 70.44 | 95.97 | 106.59 |
| ROCE % | 15.19% | 17.64% | 13.67% | 14.90% | 14.92% | 12.89% | 23.34% | 6.83% | 10.00% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.95 | 0.95 | 3.74 | 2.34 | 2.43 |
| Diluted EPS (Rs.) | 1.95 | 0.95 | 3.74 | 2.34 | 2.43 |
| Cash EPS (Rs.) | 2.99 | 2.31 | 5.63 | 4.44 | 4.61 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 28.37 | 26.42 | 25.46 | 21.73 | 19.45 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 28.37 | 26.42 | 25.46 | 21.73 | 19.45 |
| Revenue From Operations / Share (Rs.) | 34.92 | 27.54 | 55.67 | 36.59 | 42.99 |
| PBDIT / Share (Rs.) | 3.87 | 3.25 | 7.83 | 5.56 | 6.01 |
| PBIT / Share (Rs.) | 2.83 | 1.89 | 5.95 | 3.46 | 3.83 |
| PBT / Share (Rs.) | 2.61 | 1.66 | 5.59 | 3.13 | 3.30 |
| Net Profit / Share (Rs.) | 1.95 | 0.95 | 3.74 | 2.34 | 2.43 |
| PBDIT Margin (%) | 11.08 | 11.78 | 14.07 | 15.19 | 13.98 |
| PBIT Margin (%) | 8.10 | 6.85 | 10.68 | 9.44 | 8.90 |
| PBT Margin (%) | 7.45 | 6.02 | 10.04 | 8.55 | 7.68 |
| Net Profit Margin (%) | 5.57 | 3.46 | 6.71 | 6.38 | 5.65 |
| Return on Networth / Equity (%) | 6.86 | 3.61 | 14.67 | 10.75 | 12.48 |
| Return on Capital Employeed (%) | 9.24 | 6.65 | 21.95 | 15.14 | 18.53 |
| Return On Assets (%) | 5.71 | 2.75 | 10.64 | 6.65 | 6.52 |
| Long Term Debt / Equity (X) | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 |
| Total Debt / Equity (X) | 0.03 | 0.03 | 0.03 | 0.13 | 0.41 |
| Asset Turnover Ratio (%) | 1.02 | 0.78 | 1.59 | 1.01 | 1.27 |
| Current Ratio (X) | 5.14 | 2.42 | 2.44 | 1.75 | 1.40 |
| Quick Ratio (X) | 3.95 | 1.50 | 1.92 | 1.33 | 0.99 |
| Inventory Turnover Ratio (X) | 7.03 | 3.08 | 7.48 | 3.53 | 4.18 |
| Interest Coverage Ratio (X) | 17.19 | 14.34 | 22.25 | 17.08 | 11.49 |
| Interest Coverage Ratio (Post Tax) (X) | 9.65 | 5.22 | 11.62 | 8.17 | 5.64 |
| Enterprise Value (Cr.) | 152.60 | 157.16 | 97.08 | 123.80 | 63.32 |
| EV / Net Operating Revenue (X) | 3.96 | 5.18 | 1.58 | 3.07 | 1.34 |
| EV / EBITDA (X) | 35.75 | 43.93 | 11.25 | 20.20 | 9.56 |
| MarketCap / Net Operating Revenue (X) | 4.07 | 5.21 | 1.58 | 3.11 | 1.29 |
| Price / BV (X) | 5.01 | 5.43 | 3.46 | 5.23 | 2.85 |
| Price / Net Operating Revenue (X) | 4.07 | 5.21 | 1.58 | 3.11 | 1.29 |
| EarningsYield | 0.01 | 0.01 | 0.04 | 0.02 | 0.04 |
After reviewing the key financial ratios for Arvee Laboratories (India) Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.95. This value is below the healthy minimum of 5. It has increased from 0.95 (Mar 24) to 1.95, marking an increase of 1.00.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.95. This value is below the healthy minimum of 5. It has increased from 0.95 (Mar 24) to 1.95, marking an increase of 1.00.
- For Cash EPS (Rs.), as of Mar 25, the value is 2.99. This value is below the healthy minimum of 3. It has increased from 2.31 (Mar 24) to 2.99, marking an increase of 0.68.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 28.37. It has increased from 26.42 (Mar 24) to 28.37, marking an increase of 1.95.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 28.37. It has increased from 26.42 (Mar 24) to 28.37, marking an increase of 1.95.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 34.92. It has increased from 27.54 (Mar 24) to 34.92, marking an increase of 7.38.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 3.87. This value is within the healthy range. It has increased from 3.25 (Mar 24) to 3.87, marking an increase of 0.62.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.83. This value is within the healthy range. It has increased from 1.89 (Mar 24) to 2.83, marking an increase of 0.94.
- For PBT / Share (Rs.), as of Mar 25, the value is 2.61. This value is within the healthy range. It has increased from 1.66 (Mar 24) to 2.61, marking an increase of 0.95.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.95. This value is below the healthy minimum of 2. It has increased from 0.95 (Mar 24) to 1.95, marking an increase of 1.00.
- For PBDIT Margin (%), as of Mar 25, the value is 11.08. This value is within the healthy range. It has decreased from 11.78 (Mar 24) to 11.08, marking a decrease of 0.70.
- For PBIT Margin (%), as of Mar 25, the value is 8.10. This value is below the healthy minimum of 10. It has increased from 6.85 (Mar 24) to 8.10, marking an increase of 1.25.
- For PBT Margin (%), as of Mar 25, the value is 7.45. This value is below the healthy minimum of 10. It has increased from 6.02 (Mar 24) to 7.45, marking an increase of 1.43.
- For Net Profit Margin (%), as of Mar 25, the value is 5.57. This value is within the healthy range. It has increased from 3.46 (Mar 24) to 5.57, marking an increase of 2.11.
- For Return on Networth / Equity (%), as of Mar 25, the value is 6.86. This value is below the healthy minimum of 15. It has increased from 3.61 (Mar 24) to 6.86, marking an increase of 3.25.
- For Return on Capital Employeed (%), as of Mar 25, the value is 9.24. This value is below the healthy minimum of 10. It has increased from 6.65 (Mar 24) to 9.24, marking an increase of 2.59.
- For Return On Assets (%), as of Mar 25, the value is 5.71. This value is within the healthy range. It has increased from 2.75 (Mar 24) to 5.71, marking an increase of 2.96.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.03.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.03. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.02. It has increased from 0.78 (Mar 24) to 1.02, marking an increase of 0.24.
- For Current Ratio (X), as of Mar 25, the value is 5.14. This value exceeds the healthy maximum of 3. It has increased from 2.42 (Mar 24) to 5.14, marking an increase of 2.72.
- For Quick Ratio (X), as of Mar 25, the value is 3.95. This value exceeds the healthy maximum of 2. It has increased from 1.50 (Mar 24) to 3.95, marking an increase of 2.45.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 7.03. This value is within the healthy range. It has increased from 3.08 (Mar 24) to 7.03, marking an increase of 3.95.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 17.19. This value is within the healthy range. It has increased from 14.34 (Mar 24) to 17.19, marking an increase of 2.85.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 9.65. This value is within the healthy range. It has increased from 5.22 (Mar 24) to 9.65, marking an increase of 4.43.
- For Enterprise Value (Cr.), as of Mar 25, the value is 152.60. It has decreased from 157.16 (Mar 24) to 152.60, marking a decrease of 4.56.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.96. This value exceeds the healthy maximum of 3. It has decreased from 5.18 (Mar 24) to 3.96, marking a decrease of 1.22.
- For EV / EBITDA (X), as of Mar 25, the value is 35.75. This value exceeds the healthy maximum of 15. It has decreased from 43.93 (Mar 24) to 35.75, marking a decrease of 8.18.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.07. This value exceeds the healthy maximum of 3. It has decreased from 5.21 (Mar 24) to 4.07, marking a decrease of 1.14.
- For Price / BV (X), as of Mar 25, the value is 5.01. This value exceeds the healthy maximum of 3. It has decreased from 5.43 (Mar 24) to 5.01, marking a decrease of 0.42.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.07. This value exceeds the healthy maximum of 3. It has decreased from 5.21 (Mar 24) to 4.07, marking a decrease of 1.14.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Arvee Laboratories (India) Ltd:
- Net Profit Margin: 5.57%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 9.24% (Industry Average ROCE: 12.99%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 6.86% (Industry Average ROE: 25.41%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 9.65
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.95
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 446 (Industry average Stock P/E: 62.4)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.03
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 5.57%
Fundamental Analysis of Arvee Laboratories (India) Ltd
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Speciality - Others | 403, Entice, Nr. Jayantilal Park BRTS, Ahmedabad Gujarat 380058 | compliance@arveelabs.com http://www.arveelabs.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Shalin Sudhakarbhai Patel | Managing Director |
| Mr. Shalin Bharat Chokshi | Whole Time Director |
| Mrs. Neetu Rishi Jalan | Independent Director |
| Mr. Dipen Ashit Dalal | Independent Director |
| Mr. Sachin Kanwarlal Kansal | Independent Director |
| Ms. Shalini Hitesh Jalan | Additional Director |
Arvee Laboratories (India) Ltd. Share Price Update | |
|---|---|
| Share Price | Value |
| Today | ₹186.25 |
| Previous Day | ₹183.70 |
FAQ
What is the intrinsic value of Arvee Laboratories (India) Ltd?
Arvee Laboratories (India) Ltd's intrinsic value (as of 04 December 2025) is 738.50 which is 355.86% higher the current market price of 162.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 179 Cr. market cap, FY2025-2026 high/low of 233/127, reserves of ₹20.42 Cr, and liabilities of 40.58 Cr.
What is the Market Cap of Arvee Laboratories (India) Ltd?
The Market Cap of Arvee Laboratories (India) Ltd is 179 Cr..
What is the current Stock Price of Arvee Laboratories (India) Ltd as on 04 December 2025?
The current stock price of Arvee Laboratories (India) Ltd as on 04 December 2025 is 162.
What is the High / Low of Arvee Laboratories (India) Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Arvee Laboratories (India) Ltd stocks is 233/127.
What is the Stock P/E of Arvee Laboratories (India) Ltd?
The Stock P/E of Arvee Laboratories (India) Ltd is 446.
What is the Book Value of Arvee Laboratories (India) Ltd?
The Book Value of Arvee Laboratories (India) Ltd is 28.5.
What is the Dividend Yield of Arvee Laboratories (India) Ltd?
The Dividend Yield of Arvee Laboratories (India) Ltd is 0.00 %.
What is the ROCE of Arvee Laboratories (India) Ltd?
The ROCE of Arvee Laboratories (India) Ltd is 10.0 %.
What is the ROE of Arvee Laboratories (India) Ltd?
The ROE of Arvee Laboratories (India) Ltd is 7.12 %.
What is the Face Value of Arvee Laboratories (India) Ltd?
The Face Value of Arvee Laboratories (India) Ltd is 10.0.